Vnitr Lek 2017, 63(9):598-603 | DOI: 10.36290/vnl.2017.119

Anabolic steroid induced hypogonadism in men: overview and case report

Luboslav Stárka1,*, Michaela Dušková1, Lucie Kolátorová1, Oldřich Lapčík1,2
1 Endokrinologický ústav Praha
2 Fakulta potravinářské a biochemické technologie, VŠCHT, Praha

An important potential consequence of the anabolic steroid misuse is hypogonadotropic hypogonadism due to the inhibition of pituitary secretion of gonadotropins. By the symptoms as testicular atrophy, spermatogenic and fertility disturbances or dysfunction in sexual life, the anabolic steroids induced hypogonadism (ASIH) could be differentiated from organic hypogonadotropic hypogonadism only with difficulty unless the misuse is reported by the user. When diagnosed, the crucial step in the therapy is the stop of anabolic use. Convalescence lasts usually several months or even more than one year. First could be seen the retreat of testicular atrophy followed by the rearrangement of spermatogenesis. The users mainly well informed from internet use for amelioration of the symptoms injections of human choriogonadotropin (hCG), selective estrogen receptor modulators (SERM) or aromatase inhibitors.

Keywords: anabolic steroids; doping; hypogonadotropic hypogonadism; side effects

Received: July 21, 2017; Accepted: September 4, 2017; Published: September 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stárka L, Dušková M, Kolátorová L, Lapčík O. Anabolic steroid induced hypogonadism in men: overview and case report. Vnitr Lek. 2017;63(9):598-603. doi: 10.36290/vnl.2017.119.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Boks MN, Tiebosch AT, van der Waaij LA. A jaundiced bodybuilder. Cholestatic hepatitis as side effect of injectable anabolic-androgenic steroids. J Sports Sci 2017; 35(22): 2262-2264. Go to original source... Go to PubMed...
    2. Büttner A, Thieme D. Side effects of anabolic androgenic steroids: pathological findings and structure-activity relationships. Handb Exp Pharmacol. 2010; (195): 459-484. Dostupné z DOI: <http://dx.doi.org/10.1007/978-3-540-79088-4_19>. Go to original source... Go to PubMed...
    3. Coward RM, Rajanahally S, Kovac JR et al. Anabolic steroid induced hypogonadism in young men. J Urol 2013; 190(6): 2200-2205. Dostupné z DOI: <http://dx.doi.org/10.1016/j.juro.2013.06.010>. Go to original source... Go to PubMed...
    4. El Osta R, Almont T, Diligent C et al. Anabolic steroids abuse and male infertility. Basic Clin Androl 2016; 26: 2. Dostupné z DOI: <http://dx.doi.org/10.1186/s12610-016-0029-4>. Go to original source... Go to PubMed...
    5. Hampl R, Stárka L, Šnajderová M et al. Laboratorní test na odkrytí necitlivosti na androgeny pomocí sexuální hormony vázajícího globulinu (SHBG). Vnitř Lék 1992; 38(9): 879-886. Go to PubMed...
    6. Heresová J, Hampl R, Stárka L et al. Léčba oligozoospermie tamoxifenem. Česk Gynekol 1988; 53(3): 185-191. Go to PubMed...
    7. Huhtaniemi I. Anabolic-androgenic steroids-a double-edged sword? Int J Androl 1994; 17(2): 57-62. Go to original source... Go to PubMed...
    8. Hvid-Jensen HS, Rasmussen F, Bendstrup E. Pulmonary hemorrhage following anabolic agent abuse: Two cases. Respir Med Case Rep 2016; 18: 45-47. Dostupné z DOI: <http://dx.doi.org/10.1016/j.rmcr.2016.04.001>. Go to original source... Go to PubMed...
    9. Jurášek M, Goselová S, Mikšátková P et al. Highly sensitive avidin-biotin ELISA for detection of nandrolone and testosterone in dietary supplements. Drug Test Anal 2017; 9(4): 553-560. Dostupné z DOI: <http://dx.doi.org/10.1002/dta.2005>. Go to original source... Go to PubMed...
    10. Karavolos S, Reynolds M, Panagiotopoulou N et al. Male central hypogonadism secondary to exogenous androgens: a review of the drugs and protocols highlighted by the online community of users for prevention and/or mitigation of adverse effects. Clin Endocrinol (Oxf) 2015; 82(5): 624-632. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12641>. Go to original source... Go to PubMed...
    11. Kochakian CD, Moe JG et al. The protein anabolic property of testosterone propionate in normal, castrated, adrenalectomized and hypophysectomized rats. Fed Proc 1947; 6(1 Pt 2): 144.
    12. Kochakian CD. How it was. Anabolic actions of steroids and remembrances. Alabama Univ School Med: Birmingham 1984. ASIN B0006EF59G.
    13. Kochakian CD. History, chemistry and pharmacodynamics of anabolic-androgenic steroids. Wien Med Wochenschr 1993; 143(14-15): 359-363. Go to PubMed...
    14. Kovac JR, Scovell J, Ramasamy R et al. Men regret anabolic steroid use due to a lack of comprehension regarding the consequences on future fertility. Andrologia 2015; 47(8): 872-878. Dostupné z DOI: <http://dx.doi.org/10.1111/and.12340>. Go to original source... Go to PubMed...
    15. Lachman M, Mellan J, Hampl R et al. Vzestup motility spermií po léčbě tamoxifenem. Čs Gynekol 1988; 53(3): 192-195.
    16. Lusetti M, Licata M, Silingardi E et al. Pathological changes in anabolic androgenic steroid users. J Forensic Leg Med 2015; 33: 101-104. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jflm.2015.04.014>. Go to original source... Go to PubMed...
    17. McBride JA, Coward RM Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian J Androl 2016; 18(3): 373-380. Dostupné z DOI: <http://dx.doi.org/10.4103/1008-682X.173938>. Go to original source... Go to PubMed...
    18. Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14(1): 55-69. Go to original source... Go to PubMed...
    19. Prokudina EA, Prchalová J, Vyšatová E et al. Analysis of anabolic androgenic steroids by direct analysis in real time ionization with time-of-flight mass spectrometry. Int J Mass Spect 2015; 392: 28-33. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijms.2015.08.022>. Go to original source...
    20. Rahnema CD, Lipshultz LI, Crosnoe LE et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril 2014; 101(5): 1271-1279. Dostupné z DOI: <http://dx.doi.org/10.1016/j.fertnstert.2014.02.002>. Go to original source... Go to PubMed...
    21. Roth MY, Page ST, Bremner WJ. Male hormonal contraception: looking back and moving forward. Andrology 2016; 4(1): 4-12. Go to original source... Go to PubMed...
    22. Seara FAC, Barbosa RAQ, de Oliveira DF et al. Administration of anabolic steroid during adolescence induces long-term cardiac hypertrophy and increases susceptibility to ischemia/reperfusion injury in adult Wistar rats. J Steroid Biochem Mol Biol 2017; 171: 34-42. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jsbmb.2017.01.012>. Go to original source... Go to PubMed...
    23. Takayanagi A, Kobayashi K, Hashimoto K et al. Case of androgenic anabolic steroid abuse caused hypogonadotropic hypogonadism. Nihon Hinyokika Gakkai Zasshi 2008; 99(7): 729-732. Go to original source... Go to PubMed...
    24. Tan RS, Scally MC. Anabolic steroid-induced hypogonadism-towards a unified hypothesis of anabolic steroid action. Med Hypotheses 2009; 72(6): 723-728. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mehy.2008.12.042>. Go to original source... Go to PubMed...
    25. Unai S, Miessau J, Karbowski P et al. Caution for anabolic androgenic steroid use: a case report of multiple organ dysfunction syndrome. Respir Care 2013; 58(12): e159-e163. Dostupné z DOI: <http://dx.doi.org/10.4187/respcare.02338>. Go to original source... Go to PubMed...
    26. Vítků J, Sosvorová L, Chlupáčová T et al. Differences in bisphenol A and estrogen levels in the plasma and seminal plasma of men with different degrees of infertility. Physiol Res 2015; 64(Suppl 2): S303-S311. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.